Amyloidosis, Familial - 33 Studies Found
Active, not recruiting |
: Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy :
|
Active, not recruiting |
: Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy :
|
Completed |
: The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin : Transthyretin Familial Amyloid Polyneuropathy : 2011-09-13 : Drug: tafamidis tafamidis meglumine 20 mg QD Other N |
Completed |
: The Effect of Diflunisal on Familial Transthyretin Amyloidosis : Amyloidosis : 2011-09-09 : Drug: Diflunisal Film-coated tablet, 250 mg twice daily, orally for approximately 2 years |
Withdrawn |
: F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH) : Cerebral Amyloid Angiopathy : 2011-06-21 |
Completed |
: Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis : Transthyretin Amyloidosis : 2010-07-27 : Drug: Doxycycline + Tauroursodeoxycholic acid doxycycline 100 mg twice a day for 12 months; tauroursodeo |
Completed |
: An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy :
: 2008-11-13 : Drug: Fx-1006A Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each |
Completed |
: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis : Transthyretin-associated Amyloidosis With Polyneuropathy : 2008-02-27 : Drug: Fx-1006A During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at t |
Recruiting |
: Transthyretin-Associated Amyloidoses Outcome Survey (THAOS) :
: 2008-02-25 : Other: None. Observational Study. |
Completed |
: Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy :
: 2003-03-07 : Drug: NC-758 (Anti amyloidotic [Aß] agent) |